A clinical-economic study of caspofungin use in the treatment of invasive candidiasis in intensive care units

Candida spp. are the fourth on the list of sepsis pathogens in patients in intensive care units. Currently the physician’s armamentarium includes a whole range of antifungal medicines that have demonstrated high clinicalmycological effectiveness in clinical trials. The aim of this study to evaluate...

Full description

Bibliographic Details
Main Authors: A. S. Kolbin, O. A. Koroleva, N. N. Klimko
Format: Article
Language:Russian
Published: Journal Infectology 2014-09-01
Series:Žurnal Infektologii
Subjects:
Online Access:https://journal.niidi.ru/jofin/article/view/284
id doaj-89bd1532cf864db5844de1b0e7767461
record_format Article
spelling doaj-89bd1532cf864db5844de1b0e77674612021-08-02T08:43:18ZrusJournal InfectologyŽurnal Infektologii 2072-67322014-09-0121425010.22625/2072-6732-2010-2-1-42-50298A clinical-economic study of caspofungin use in the treatment of invasive candidiasis in intensive care unitsA. S. Kolbin0O. A. Koroleva1N. N. Klimko2Saint-Petersburg state university, Saint-PetersburgSaint-Petersburg state university, Saint-PetersburgSaint-Petersburg Medical Academy of Postgraduate Education, Saint-PetersburgCandida spp. are the fourth on the list of sepsis pathogens in patients in intensive care units. Currently the physician’s armamentarium includes a whole range of antifungal medicines that have demonstrated high clinicalmycological effectiveness in clinical trials. The aim of this study to evaluate the clinical-economic usefulness of caspofungin therapy in the treatment of invasive candidiasis versus standard and alternative treatments in patients inintensive care units. The first time in the Russian clinical-economic analysis for targeted IC treatment in non-neutropenic patients in intensive care units who have not received primary prophylaxis with azole antimycotics, as well as in those with low (< 20%) occurrence of in vitro Candida spp. resistance to fluconazole according to national or local study results, yielded the following findings: the best strategy is initial amphotericin B therapy with subsequent switching to caspofungin in patients with ineffective initial amphotericin B therapy or those with severe adverse events.https://journal.niidi.ru/jofin/article/view/284candidiasisintensive care unitsclinicaleconomic analysis
collection DOAJ
language Russian
format Article
sources DOAJ
author A. S. Kolbin
O. A. Koroleva
N. N. Klimko
spellingShingle A. S. Kolbin
O. A. Koroleva
N. N. Klimko
A clinical-economic study of caspofungin use in the treatment of invasive candidiasis in intensive care units
Žurnal Infektologii
candidiasis
intensive care units
clinicaleconomic analysis
author_facet A. S. Kolbin
O. A. Koroleva
N. N. Klimko
author_sort A. S. Kolbin
title A clinical-economic study of caspofungin use in the treatment of invasive candidiasis in intensive care units
title_short A clinical-economic study of caspofungin use in the treatment of invasive candidiasis in intensive care units
title_full A clinical-economic study of caspofungin use in the treatment of invasive candidiasis in intensive care units
title_fullStr A clinical-economic study of caspofungin use in the treatment of invasive candidiasis in intensive care units
title_full_unstemmed A clinical-economic study of caspofungin use in the treatment of invasive candidiasis in intensive care units
title_sort clinical-economic study of caspofungin use in the treatment of invasive candidiasis in intensive care units
publisher Journal Infectology
series Žurnal Infektologii
issn 2072-6732
publishDate 2014-09-01
description Candida spp. are the fourth on the list of sepsis pathogens in patients in intensive care units. Currently the physician’s armamentarium includes a whole range of antifungal medicines that have demonstrated high clinicalmycological effectiveness in clinical trials. The aim of this study to evaluate the clinical-economic usefulness of caspofungin therapy in the treatment of invasive candidiasis versus standard and alternative treatments in patients inintensive care units. The first time in the Russian clinical-economic analysis for targeted IC treatment in non-neutropenic patients in intensive care units who have not received primary prophylaxis with azole antimycotics, as well as in those with low (< 20%) occurrence of in vitro Candida spp. resistance to fluconazole according to national or local study results, yielded the following findings: the best strategy is initial amphotericin B therapy with subsequent switching to caspofungin in patients with ineffective initial amphotericin B therapy or those with severe adverse events.
topic candidiasis
intensive care units
clinicaleconomic analysis
url https://journal.niidi.ru/jofin/article/view/284
work_keys_str_mv AT askolbin aclinicaleconomicstudyofcaspofunginuseinthetreatmentofinvasivecandidiasisinintensivecareunits
AT oakoroleva aclinicaleconomicstudyofcaspofunginuseinthetreatmentofinvasivecandidiasisinintensivecareunits
AT nnklimko aclinicaleconomicstudyofcaspofunginuseinthetreatmentofinvasivecandidiasisinintensivecareunits
AT askolbin clinicaleconomicstudyofcaspofunginuseinthetreatmentofinvasivecandidiasisinintensivecareunits
AT oakoroleva clinicaleconomicstudyofcaspofunginuseinthetreatmentofinvasivecandidiasisinintensivecareunits
AT nnklimko clinicaleconomicstudyofcaspofunginuseinthetreatmentofinvasivecandidiasisinintensivecareunits
_version_ 1721237562717110272